SCHEMBL13596361

SCHEMBL13596361

CC[C@H](C)[C@H](NC(C)=O)C(=O)NC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.41
ADAM17 P78536 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
MME P08473 1/20 0.38
ACE P12821 1/20 0.38
CPA1 P15085 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
ANPEP P15144 1/20 0.38
KDM4E B2RXH2 1/20 0.38
FPR2 P25090 2/20 0.36
ATM Q13315 1/20 0.36
GZMB P10144 2/20 0.36
HTT P42858 1/20 0.35
CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13888696 1.00 MEN1 (0.50) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL5491769 0.89 MEN1 (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL13595461 0.84 ALDH1A1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL13888704 0.82 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL18771471 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL18771491 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL8354230 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL12372143 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL19776964 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL21896518 0.81 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11399611-B2 Process for straightening keratin fibres with a heating means and denaturing agents L'OREAL (FR) 2022-08-02 US disclosed
US-7638526-B2 Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-20080089858-A1 AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM SCHERING CORPORATION 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080089858-A1 AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM GPR119, PNLIP, CYP46A1 MEN1 3422/4885KMT2A 3822/4885SMN1; SMN2 2012/4885
US-11399611-B2 Process for straightening keratin fibres with a heating means and denaturing agents KRT18, KRTCAP2, TUBB4A MEN1 3718/4885KMT2A 1602/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.